Meta-analysis: surgery tops SBRT for early-stage NSCLC

  • Cao C & al.
  • J Thorac Cardiovasc Surg
  • 15 Sep 2018

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Surgery offered better OS, cancer-specific survival (CSS), disease-free survival (DFS), and freedom from locoregional recurrence compared with stereotactic body radiation therapy (SBRT) for early-stage NSCLC, according to a new meta-analysis.

Why this matters

  • Positive study results for SBRT in inoperable NSCLC have heightened interest in the benefit of SBRT in operable patients as well.
  • The difference in outcomes may be due "at least in part to an imbalance of baseline characteristics," the authors note.

Study design

  • Meta-analysis of 23 studies.
  • Funding: NIH.

Key results

  • Surgery offered better outcomes than SBRT in matched and unmatched cohorts for OS, CSS, DFS, and freedom from recurrence:
    • OS: unmatched OR, 2.49 (P<.00001 matched or>
    • CSS: unmatched OR, 2.44 (P<.00001 matched or>
    • DFS: unmatched OR, 2.13 (P<.00001 matched or>
    • Freedom from locoregional recurrence: unmatched OR, 5.44 (P <.005 matched or>
  • SBRT offered slightly lower 30-day mortality and morbidity.

Limitations

  • Lack of randomized control trials.
  • Patient selection bias.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit